Study shows Americans overwhelmingly in favor of BTC classification
CHICAGO A study by Leo J. Shapiro & Associates released Thursday found that two-thirds of Americans believe the Food and Drug Administration should create a third-class of drugs that would require no prescription and be dispensed by the pharmacist, even if insurance doesn’t cover the cost.
According to the survey, 62 percent of consumers agreed that obtaining BTC medications from a pharmacist would be more convenient than seeing a doctor. Two thirds also agreed that BTC would allow people without the benefit of health insurance to have access to medications they may need. Among households without health insurance this belief was even stronger, 82 percent of the uninsured believed a BTC category would allow them greater access to needed medications.
However, safety and oversight were still serious concerns, the survey found. A little more than half, 53 percent, agreed that pharmacists currently have the knowledge and training to dispense BTC drugs; but 17 percent disagreed and 30 percent were either neutral or uncertain. As much as 70 percent of patients surveyed agreed that the pharmacist should communicate BTC usage to their general practitioner as a matter of practice.
Also revealing in the study was the public’s lack of confidence in the FDA to keep drugs safe and adequately monitored. Only 44 percent of respondents felt the FDA could ensure BTC drug safety. And increased liability on behalf of the pharmacist, a concern of industry, was legitimized by the survey. Should a serious problem developed with a BTC drug, 38 percent of the public would hold the pharmaceutical company most liable, 26 percent the FDA and 25 percent the pharmacist who dispensed the drug.
Respondents were interviewed in person by telephone during November 2007 in this study of 450 U.S. households.
Jason Ash named PacificHealth president and CEO
MATAWAN, N.J. PacificHealth Laboratories on Thursday named Jason Ash as the company’s president and chief operating officer, as well as a member of the company’s board, effective Jan. 3.
Ash assumes the role of president from Portman, who will continue to serve as chief executive officer, chief scientific officer and chairman.
“Jason brings a great deal of knowledge and experience in the performance beverage arena, and actually led Cadbury’s negotiations leading to their acquisition of the Accelerade and Endurox trade marks and intellectual property,” Portman stated. “Jason’s existing knowledge of our company and our growth objectives will enable him to hit the ground running and provides an excellent opportunity for PacificHealth to rapidly expand upon our existing growth strategy.”
Ash also assumes chief operating officer duties currently held by Stephen Kuchen, who will continue to serve as chief financial officer, treasurer, secretary and director.
Ash brings a decade worth of experience in commercial brand management and consumer marketing to PacificHealth, most recently serving as general manager and vice president of Cadbury Schweppes Americas Beverages Sports in the energy and water category unit.
Next announces results of Nexrutine dietary supplement study
SALINAS, Calif. Next Pharmaceuticals announced Thursday the results of a clinical study on Nexrutine, conducted at The LaValle Metabolic Institute in Cincinnati.
The study concluded that Nexrutine, when used as a dietary supplement, helps in the management of pain and/or inflammation and helps promote a restful sleep with minimal side effects.
“Suffering from pain and inflammation can be a life-changing challenge,” stated Jim LaValle, founder of The LaValle Metabolic Institute and author of many books, including Cracking the Metabolic Code and the Cox-2 Connection. “Many of our patients are relieved to find a natural remedy that is not only cardio protective, but unlike aspirin, is easy on the stomach. This study demonstrates that Nexrutine has an excellent safety profile.”
Out of the 401 participants in the study, 92 percent reported Nexrutine provided pain relief and 93 percent reported improvement in their overall condition.
Nexrutine is a proprietary blend of natural ingredients developed to address general aches and pains associated with physical activity and over-exertion.
The clinical trial was designed to be an open label, single center, clinical trial.